In a further sign of confidence returning to the euro zone, ECB President Mario Draghi was cautiously more upbeat about the economic outlook. "It's difficult to see what would force the ECB to do more on policy," after Thursday's meeting and news conference, said Jane Foley, a currency strategist at Rabobank in London. "Overall, Draghi has left the market with the impression that the ECB could be done on policy barring a significant shock," Ms Foley added. Marc Chandler, a currencies analyst at Brown Brothers Harriman, agrees. "Although some observers had favored an April move, Draghi's tone makes this seem unlikely as well," he said. The ECB president said he was encouraged by data showing that business activity in the euro zone rose to a 32-month high on Wednesday, and noted an improvement in the services sector, which accounts for the majority of job creation.
BIGGEST LOSERS: Biotechnology and health care stocks were among the biggest decliners in early trading. Vertex Pharmaceuticals and Biogen Idec were both down roughly 4 percent. Gilead Sciences was down 2 percent. The Nasdaq composite index is more heavily weighted to biotechnology and specialty pharmaceutical companies, which is part of the reason the index is down much more than the Dow or S&P 500. JOBS: The Labor Department's report of 175,000 job additions last month was much better than expected. Economists had been expecting an increase of 145,000 jobs, according to FactSet.